Home 2

Supporting individuals with Alzheimer's disease and those that care for them

Dthera Sciences (OTCQB: DTHR) is a publicly traded digital therapeutics company focused on the elderly and individuals with neurodegenerative diseases.

The Alzheimer's Disease Healthcare Crisis

5.7 million Americans are living with Alzheimer’s disease. By 2050, this number is projected to rise to to nearly 14 million

Digital Therapeutics

Digitizing evidence-based cognitive-behavioral therapies and delivering them at scale

Breakthrough Device Designation

DTHR-ALZ is the first product to receive
Breakthrough Device designation from the FDA
for the treatment of Alzheimer’s disease

Press and media

Latest news

Dthera Sciences Chief Technology Officer to Speak at CES Digital Health Summit

Dave Keene, Co-Founder and Chief Technology Officer will be speaking at CES, Digital Health Summit, A Brain and Mental Health Crisis Intervention. CES 2019, is January 8-11, 2019 in Las Vegas

Dthera Sciences to Provide Corporate Update at the Digital Medicine and Medtech Showcase

Dthera™ Sciences (OTCQB:DTHR), the leading digital therapeutic company focusing on the elderly, will be presenting at the Digital Medicine and MedTech Showcase 2019 on Tuesday, January 8 at 10:30am PST in San Francisco.

Connect with us

Subscribe to our e-mail list and stay up-to-date with all our news.